Dicot Pharma

Dicot Pharma is a Swedish clinical-stage pharmaceutical company focused on developing LIB-01, a novel treatment candidate for erectile dysfunction. The company’s work centers on drug discovery, clinical development, and intellectual property protection for a global sexual-health market.

— Dicot Pharma
%
Drug candidate development100% Development of LIB-01 through preclinical and clinical stages.
Intellectual property0% Patent families, know-how, and related protection of the LIB-01 platform.
Partnership commercialization0% Potential upfront, milestone, and royalty economics from licensing or partnering.

Dicot Pharma does not yet sell a commercial product; its near-term counterparties are clinical trial sites, contract...

  • Clinical research partnersprimary

    Trial sites, investigators, and CRO-type partners that execute phase studies for LIB-01.

  • Manufacturing partnersprimary

    Specialized pharmaceutical manufacturers that produce study drug and placebo tablets.

  • Pharmaceutical licenseesprimary

    Potential industrial partners that could outlicense development and commercialization rights.

  • Future patients and prescriberssecondary

    Men treated for erectile dysfunction and the physicians who prescribe the eventual product.

  • Capital providersprimary

    Equity investors and warrant holders financing the clinical development program.

Dicot Pharma is headquartered in Sweden and develops LIB-01 for a global market. Its clinical work has involved...

  • •Headquartered in Sweden
  • •Clinical study sites span three countries
  • •Product target market is global, not country-specific
  • •Manufacturing and partners are international
  • •Commercial exposure will depend on future licensing territories

Dicot Pharma’s strategy is to advance LIB-01 through clinical development and use data to support partnering or...

01
Advance LIB-01 through clinical developmentshort-term

Clinical data are the main value driver for a precommercial biotech and determine partnering potential.

02
Secure industrial and financial partnershipsshort-term

Partnerships can fund development and convert clinical progress into non-dilutive economics.

03
Protect intellectual propertymedium-term

Patent and know-how protection are essential to preserve exclusivity and bargaining power.

04
Broaden the product portfoliomedium-term

Additional indications or assets could reduce single-asset dependence and expand long-term value.

Dicot Pharma’s main risks are typical of a single-asset clinical biotech: clinical failure, funding needs, and...

critical

Clinical development risk

LIB-01 is still in development, so efficacy, safety, and trial design outcomes remain uncertain.

Scope
Phase 2 and later-stage studies
Materiality
high
high

Capital requirements

A precommercial biotech typically consumes cash before any product revenue is generated.

Scope
Financing of ongoing and future trials
Materiality
high
high

Key personnel dependence

The business relies heavily on management, board members, and specialized scientific expertise.

Scope
Leadership, clinical, and IP functions
Materiality
medium
high

Intellectual property protection

Competitors may challenge patents or develop alternative compounds and know-how.

Scope
LIB-01 exclusivity and partnering leverage
Materiality
high
medium

Partnering and commercialization risk

Future value depends on securing industrial partners on acceptable terms.

Scope
Outlicensing and royalty economics
Materiality
medium
Expensing of development costs
No capitalized development asset or future amortization from current projects
Clinical trial cost timing
Comparability between quarters is limited
Share-based compensation
Affects operating expenses and equity
Warrants and equity financing
Dilution and financing capacity

Connect Biopharma Holdings Ltd

CNTB · Pharmaceutical Preparations

CITIUS ONCOLOGY, INC.

CTOR · Pharmaceutical Preparations

Dianthus Therapeutics, Inc. /DE/

DNTH · Pharmaceutical Preparations

Sionna Therapeutics, Inc.

SION · Pharmaceutical Preparations

CYTOKINETICS INC

CYTK · Pharmaceutical Preparations

CAPRICOR THERAPEUTICS, INC.

CAPR · Pharmaceutical Preparations

: 11/08/2026